Well, at least there are a lot of early-stage treatments getting mentioned in the press right now -- it's better than nothing...
Argos Therapeutics, Beckman Coulter Sign License Agreement; CD83 Licensure to Advance Work on Autoimmune Disorders, Transplant Rejection Therapy
BUSINESS WIRE - April 26, 2006 - Argos Therapeutics, a company pioneering new approaches in immunotherapy, announced today that it has entered into an agreement with California-based Beckman Coulter granting Argos exclusive therapeutic use rights ...
Read more : CD83
| Views :
1368 | Replies :